The FDA issued its first approval of a Digital Medicine, ABILIFY MYCITE®, a new innovative treatment option in mental health. Otsuka, with the help of Proteus Inc., developed a sensor as part of the pill that communicates externally to provide confirmation the pill was ingested, along with details about it. This is for serious mental illness and can be monitored by others to ensure required medication is being properly taken/administered. Otsuka’s commercialization approach is to launch in 2018, in collaboration with carefully selected health plans and providers in the United States. You can find out more in the press release at the link provided. Otsuka And Proteus® Announce The First U.S. FDA Approval Of A Digital Medicine System: ABILIFY MYCITE® (aripiprazole tablets with sensor)
